Raltegravir ||| S:0 E:11 ||| NNP
:  ||| S:11 E:13 ||| :
molecular  ||| S:13 E:23 ||| JJ
basis  ||| S:23 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
its  ||| S:32 E:36 ||| PRP$
mechanism  ||| S:36 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
action  ||| S:49 E:56 ||| NN
Integration  ||| S:56 E:68 ||| NNS
of  ||| S:68 E:71 ||| IN
the  ||| S:71 E:75 ||| DT
HIV-1  ||| S:75 E:81 ||| NNP
viral  ||| S:81 E:87 ||| JJ
DNA  ||| S:87 E:91 ||| NN
generated  ||| S:91 E:101 ||| VBD
by  ||| S:101 E:104 ||| IN
reverse  ||| S:104 E:112 ||| JJ
transcription  ||| S:112 E:126 ||| NN
of  ||| S:126 E:129 ||| IN
the  ||| S:129 E:133 ||| DT
RNA  ||| S:133 E:137 ||| NNP
genome  ||| S:137 E:144 ||| NN
into  ||| S:144 E:149 ||| IN
the  ||| S:149 E:153 ||| DT
host  ||| S:153 E:158 ||| NN
cell  ||| S:158 E:163 ||| NN
chromosomes  ||| S:163 E:175 ||| NN
is  ||| S:175 E:178 ||| VBZ
a  ||| S:178 E:180 ||| DT
key  ||| S:180 E:184 ||| JJ
step  ||| S:184 E:189 ||| NN
of  ||| S:189 E:192 ||| IN
viral  ||| S:192 E:198 ||| JJ
replication ||| S:198 E:209 ||| NN
,  ||| S:209 E:211 ||| ,
catalyzed  ||| S:211 E:221 ||| VBG
by  ||| S:221 E:224 ||| IN
the  ||| S:224 E:228 ||| DT
viral  ||| S:228 E:234 ||| JJ
integrase ||| S:234 E:243 ||| NN
.  ||| S:243 E:245 ||| .
In  ||| S:245 E:248 ||| IN
October  ||| S:248 E:256 ||| NNP
2007 ||| S:256 E:260 ||| CD
,  ||| S:260 E:262 ||| ,
the  ||| S:262 E:266 ||| DT
first  ||| S:266 E:272 ||| JJ
integrase  ||| S:272 E:282 ||| JJ
inhibitor ||| S:282 E:291 ||| NN
,  ||| S:291 E:293 ||| ,
raltegravir ||| S:293 E:304 ||| NN
,  ||| S:304 E:306 ||| ,
was  ||| S:306 E:310 ||| VBD
approved  ||| S:310 E:319 ||| VBN
for  ||| S:319 E:323 ||| IN
clinical  ||| S:323 E:332 ||| JJ
use  ||| S:332 E:336 ||| NN
under  ||| S:336 E:342 ||| IN
the  ||| S:342 E:346 ||| DT
name  ||| S:346 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
Isentress  ||| S:354 E:364 ||| NNP
superset ||| S:364 E:372 ||| NN
.  ||| S:372 E:374 ||| .
The  ||| S:374 E:378 ||| DT
results  ||| S:378 E:386 ||| NNS
of  ||| S:386 E:389 ||| IN
the  ||| S:389 E:393 ||| DT
various  ||| S:393 E:401 ||| JJ
clinical  ||| S:401 E:410 ||| JJ
trials  ||| S:410 E:417 ||| NNS
that  ||| S:417 E:422 ||| WDT
have  ||| S:422 E:427 ||| VBP
evaluated  ||| S:427 E:437 ||| VBN
raltegravir  ||| S:437 E:449 ||| NNS
have  ||| S:449 E:454 ||| VBP
been  ||| S:454 E:459 ||| VBN
very  ||| S:459 E:464 ||| RB
encouraging  ||| S:464 E:476 ||| VBG
with  ||| S:476 E:481 ||| IN
regard  ||| S:481 E:488 ||| NN
to  ||| S:488 E:491 ||| TO
the  ||| S:491 E:495 ||| DT
immunological  ||| S:495 E:509 ||| NN
and  ||| S:509 E:513 ||| CC
virological  ||| S:513 E:525 ||| JJ
efficacy  ||| S:525 E:534 ||| NN
and  ||| S:534 E:538 ||| CC
tolerance ||| S:538 E:547 ||| NN
.  ||| S:547 E:549 ||| .
However ||| S:549 E:556 ||| RB
,  ||| S:556 E:558 ||| ,
as  ||| S:558 E:561 ||| RB
observed  ||| S:561 E:570 ||| VBN
for  ||| S:570 E:574 ||| IN
other  ||| S:574 E:580 ||| JJ
anti-retrovirals ||| S:580 E:596 ||| NN
,  ||| S:596 E:598 ||| ,
specific  ||| S:598 E:607 ||| JJ
resistance  ||| S:607 E:618 ||| NN
mutations  ||| S:618 E:628 ||| NNS
have  ||| S:628 E:633 ||| VBP
been  ||| S:633 E:638 ||| VBN
identified  ||| S:638 E:649 ||| VBN
in  ||| S:649 E:652 ||| IN
patients  ||| S:652 E:661 ||| NNS
failing  ||| S:661 E:669 ||| VBG
to  ||| S:669 E:672 ||| TO
respond  ||| S:672 E:680 ||| VB
to  ||| S:680 E:683 ||| TO
treatment  ||| S:683 E:693 ||| NN
with  ||| S:693 E:698 ||| IN
raltegravir ||| S:698 E:709 ||| NN
.  ||| S:709 E:711 ||| .
Although  ||| S:711 E:720 ||| IN
knowledge  ||| S:720 E:730 ||| NN
of  ||| S:730 E:733 ||| IN
the  ||| S:733 E:737 ||| DT
integrase  ||| S:737 E:747 ||| JJ
structural  ||| S:747 E:758 ||| JJ
biology  ||| S:758 E:766 ||| NN
remains  ||| S:766 E:774 ||| VBZ
fragmentary ||| S:774 E:785 ||| VBN
,  ||| S:785 E:787 ||| ,
the  ||| S:787 E:791 ||| DT
structures  ||| S:791 E:802 ||| NNS
and  ||| S:802 E:806 ||| CC
modeling  ||| S:806 E:815 ||| JJ
data  ||| S:815 E:820 ||| NNS
available  ||| S:820 E:830 ||| JJ
might  ||| S:830 E:836 ||| MD
provide  ||| S:836 E:844 ||| VB
relevant  ||| S:844 E:853 ||| JJ
clues  ||| S:853 E:859 ||| NNS
on  ||| S:859 E:862 ||| IN
the  ||| S:862 E:866 ||| DT
origin  ||| S:866 E:873 ||| NN
of  ||| S:873 E:876 ||| IN
the  ||| S:876 E:880 ||| DT
emergence  ||| S:880 E:890 ||| NN
of  ||| S:890 E:893 ||| IN
these  ||| S:893 E:899 ||| DT
resistance  ||| S:899 E:910 ||| NN
mutations ||| S:910 E:919 ||| NNS
.  ||| S:919 E:921 ||| .
In  ||| S:921 E:924 ||| IN
this  ||| S:924 E:929 ||| DT
review ||| S:929 E:935 ||| NN
,  ||| S:935 E:937 ||| ,
we  ||| S:937 E:940 ||| PRP
describe  ||| S:940 E:949 ||| VBP
the  ||| S:949 E:953 ||| DT
mechanism  ||| S:953 E:963 ||| NN
of  ||| S:963 E:966 ||| IN
action  ||| S:966 E:973 ||| NN
of  ||| S:973 E:976 ||| IN
this  ||| S:976 E:981 ||| DT
drug  ||| S:981 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
the  ||| S:990 E:994 ||| DT
main  ||| S:994 E:999 ||| JJ
data  ||| S:999 E:1004 ||| NNS
relating  ||| S:1004 E:1013 ||| VBG
to  ||| S:1013 E:1016 ||| TO
its  ||| S:1016 E:1020 ||| PRP$
use  ||| S:1020 E:1024 ||| NN
in  ||| S:1024 E:1027 ||| IN
vivo ||| S:1027 E:1031 ||| NN
,  ||| S:1031 E:1033 ||| ,
together  ||| S:1033 E:1042 ||| RB
with  ||| S:1042 E:1047 ||| IN
recent  ||| S:1047 E:1054 ||| JJ
structural  ||| S:1054 E:1065 ||| JJ
data  ||| S:1065 E:1070 ||| NNS
important  ||| S:1070 E:1080 ||| JJ
to  ||| S:1080 E:1083 ||| TO
our  ||| S:1083 E:1087 ||| PRP$
understanding  ||| S:1087 E:1101 ||| NN
of  ||| S:1101 E:1104 ||| IN
the  ||| S:1104 E:1108 ||| DT
origin  ||| S:1108 E:1115 ||| NN
of  ||| S:1115 E:1118 ||| IN
viral  ||| S:1118 E:1124 ||| JJ
resistance ||| S:1124 E:1134 ||| NN
.  ||| S:1134 E:1136 ||| .
